8 research outputs found
HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase
The Trans-activator protein (Tat) of human immunodeficiency virus (HIV)
is a pleiotropic protein involved in different aspects of AIDS pathogenesis. As
a number of viral proteins Tat is suspected to disturb mitochondrial function.
We prepared pure synthetic full-length Tat by native chemical ligation (NCL),
and Tat peptides, to evaluate their direct effects on isolated mitochondria.
Submicromolar doses of synthetic Tat cause a rapid dissipation of the
mitochondrial transmembrane potential (ΔΨm) as well as
cytochrome c release in mitochondria isolated from mouse liver, heart,
and brain. Accordingly, Tat decreases substrate oxidation by mitochondria
isolated from these tissues, with oxygen uptake being initially restored by
adding cytochrome c. The anion-channel inhibitor
4,4′-diisothiocyanostilbene-2,2′-disulfonic acid (DIDS) protects
isolated mitochondria against Tat-induced mitochondrial membrane
permeabilization (MMP), whereas ruthenium red, a ryanodine receptor blocker,
does not. Pharmacologic inhibitors of the permeability transition pore,
Bax/Bak inhibitors, and recombinant Bcl-2 and Bcl-XL proteins do not reduce
Tat-induced MMP. We finally observed that Tat inhibits cytochrome c
oxidase (COX) activity in disrupted mitochondria isolated from liver, heart, and
brain of both mouse and human samples, making it the first described viral
protein to be a potential COX inhibitor
HTLV-1 Evades Type I Interferon Antiviral Signaling by Inducing the Suppressor of Cytokine Signaling 1 (SOCS1)
Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of Adult T cell Leukemia (ATL) and the neurological disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although the majority of HTLV-1–infected individuals remain asymptomatic carriers (AC) during their lifetime, 2–5% will develop either ATL or HAM/TSP, but never both. To better understand the gene expression changes in HTLV-1-associated diseases, we examined the mRNA profiles of CD4+ T cells isolated from 7 ATL, 12 HAM/TSP, 11 AC and 8 non-infected controls. Using genomic approaches followed by bioinformatic analysis, we identified gene expression pattern characteristic of HTLV-1 infected individuals and particular disease states. Of particular interest, the suppressor of cytokine signaling 1—SOCS1—was upregulated in HAM/TSP and AC patients but not in ATL. Moreover, SOCS1 was positively correlated with the expression of HTLV-1 mRNA in HAM/TSP patient samples. In primary PBMCs transfected with a HTLV-1 proviral clone and in HTLV-1-transformed MT-2 cells, HTLV-1 replication correlated with induction of SOCS1 and inhibition of IFN-α/β and IFN-stimulated gene expression. Targeting SOCS1 with siRNA restored type I IFN production and reduced HTLV-1 replication in MT-2 cells. Conversely, exogenous expression of SOCS1 resulted in enhanced HTLV-1 mRNA synthesis. In addition to inhibiting signaling downstream of the IFN receptor, SOCS1 inhibited IFN-β production by targeting IRF3 for ubiquitination and proteasomal degradation. These observations identify a novel SOCS1 driven mechanism of evasion of the type I IFN antiviral response against HTLV-1